Concepedia

G Temperley

GT

Statistics

Publications

5

Citations

153

H-Index

5

Active since

1997

Affiliations

Ligand Pharmaceuticals (United States)(Current)

G Temperley is an author at Ligand Pharmaceuticals (United States) specializing in medicine, oncology, and chemotherapy.

Publications per year

1997–2009

5

Publications

5

Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT I

Rodryg Ramlau, Petr Zatloukal, Jacek Jassem et al. · Journal of Clinical Oncology · 2008 · 90 citations · Full text

Medicine, Oncology, Pharmacology +10

A randomized phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Jacek Jassem, Petr Zatloukal, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2005 · 25 citations

Medicine, Oncology, Pharmacology +12

Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.

L. Ezcurdia, S Jovtis, E. Mickiewicz et al. · PubMed · 1997 · 14 citations

Medicine, Oncology, Pharmacology +13

Treatment of Non-Small Cell Lung Cancer with Ifosfamide (IFO) + 4’-Epiadriamycin (EPI) + Platinum vs. IFO + EPI: A GETLAC Study

N Brocato, M. Bruno, Carlos E. Araujo et al. · Oncology · 2009 · 14 citations

Medicine, Oncology, Pharmacology +11

Phase II of doxorubicin/taxol in metastatic breast cancer

Claudia Pazos, E. Mickiewicz, María Rosa Di Notto et al. · Breast Cancer Research and Treatment · 1999 · 10 citations

Medicine, Oncology, Pharmacology +14

1–5 of 5